Dr Reddy’s begins process to obtain emergency use authorisation for Sputnik V

The vaccine is undergoing phase-3 clinical trial in India

Dr Reddy’s begins process to obtain emergency use authorisation for Sputnik V

A medical specialist holds a vial of Sputnik V vaccine in Moscow, Russia, on January 18, 2021. Reuters

New Delhi, February 19

Dr Reddy’s Laboratories on Friday said it has approached drugs regulator DCGI for emergency use authorisation (EUA) for COVID-19 vaccine Sputnik V.

As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21, 2021, Dr Reddy’s said in a statement.

In September last year, the Hyderabad-based firm partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The vaccine is undergoing phase 3 clinical trial in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod for two COVID-19 vaccines - Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca , being manufactured by Serum Institute of India in Pune.

The vaccines are being administered to frontline workers across the country.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia, the statement said.

The vaccine also maintained a consistent efficacy at 91.8 per cent even among the group of 2,144 volunteers over 60 years old.

“The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the fight against COVID-19. The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India,” Dr Reddy’s Laboratories Co-chairman and Managing Director G V Prasad said.

Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia on August 11, 2020 and became the world’s first registered vaccine against COVID-19 based on the human adenoviral vector platform.

Sputnik V has already received approval in 26 countries and has been administered to more than 2 million people worldwide. PTI

Top Stories

Population-based Covid vaccination from Monday, registrations open from 9 am

Population-based Covid vaccination from Monday, registrations open from 9 am

Appointments can be booked between 9 am and 3 pm

India records 16,752 fresh COVID cases, biggest single-day jump in 30 days

India records 16,752 fresh COVID cases, biggest single-day jump in 30 days

Death toll mounts to 1,57,051 with 113 fresh fatalities

Mann ki Baat: Aatmanirbhar Bharat is national spirit, says PM Modi

Mann ki Baat: Aatmanirbhar Bharat is national spirit, says PM Modi

Calls for 100-day campaign to clean up water bodies, harvest...

Azad praises PM Modi for being ‘frank’ about his past as ‘tea-seller’

Azad praises PM Modi for being ‘frank’ about his past as ‘tea-seller’

Remarks come a day after Azad and other ‘G-23’ dissident lea...

Punjab’s budget session from Monday, fireworks likely

Punjab’s budget session from Monday, fireworks likely

Opposition to corner govt over ‘failure’ to honour its poll ...

Cities

View All